In a post on X, Hims & Hers' chief executive, Andrew Dudum, said that the company will "continue to offer access to personalised treatments as allowed by law to meet patient needs," and will be "closely monitoring" the semaglutide supply chain, given that Novo Nordisk "stated two weeks ago that it would continue to have 'capacity limitations' and 'expected continued periodic supply constraints and related drug shortage notifications'." For its part, the FDA said it "has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved." The agency will continue to allow compounders to provide semaglutide to patients on a temporary basis "to avoid unnecessary disruption to patient treatment." State-licensed pharmacy or physician compounders can continue to do so until 22nd April, while outsourcing facilities have a deadline of 22nd May

There are other new drugs that are closely related however, such as tirzepatide, found in Mounjaro and Zepbound
When criteria are met, the insurance company approves brand coverage
Achieve Your Weight Loss Goals with Ozempic Discover the benefits of Ozempic, FDA-cleared medications designed to support your weight loss and metabolic health goals
Others may experience side effects they didnt have with their prior GLP-1
Protein and fibre help you feel full